Related Experiment Video
Updated: Jun 3, 2025
Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
Published on: July 27, 2022
Sustained release of Ambrisentan solid lipid nanoparticles for the treatment of hypertension: Melt emulsification
Harshada Shewale1, Abhishek Kanugo2
1SVKM's NMIMS School of Pharmacy and Technology Management Shirpur, Dhule 425405, India.
Objective:
The beneficial usefulness is limited because of its deprived solubility and bioavailability. The recent work deals with the advancement of solid lipid nanoparticles of Ambrisentan for the effective therapy of pulmonary hypertension intended for oral delivery.
Material And Methods:
The solid lipid nanoparticles of Ambrisentan were developed using the melt emulsification method. The characterization of Ambrisentan was carried out with FTIR, DSC, and crystalline nature with XRD. The optimization was accomplished with the Box-Behnken design. The glyceryl monostearate (GMS), Tween 80, and sonication time were considered independent factors and the particle size, and entrapment efficiency were the critical quality attributes in the development of SLN.
Results:
The compatibility, thermal nature, and crystalline behavior were confirmed with FTIR, DSC, and XRD respectively. The preferred batch F10 indicated a particle size of 166.7nm and an entrapment efficiency of 83.96%. The cumulative percentage of drug dissolved from the optimized Ambrisentan-loaded SLN was 87.68% after 24h indicating a sustained release pattern. Furthermore, after lyophilization and estimated with scanning electron microscopy a particle size of 153.5 to 179.8nm was confirmed. The lyophilized powder is intended for oral delivery and has significant bioavailability, minimizing the chances of mortality due to its sustained release action.
Conclusion:
The significant improvement in solubility of Ambrisentan was achieved through solid lipid nanoparticles which facilitates greater efficacy.
More Related Videos
11:35Constant Pressure-controlled Extrusion Method for the Preparation of Nano-sized Lipid Vesicles
Published on: June 22, 2012
13:54A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
Published on: August 18, 2023
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18Drug Delivery: Enteral Route
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...